Login
$NRXP
$2.13 -$0.02 (0.93%) Pre-market

$NRXP SEC Filings

Filed On Filing
16 Nov 2026 FORM 10-Q
05 Nov 2026 FORM DEFA14A
05 Nov 2026 Proxy statement: annual meeting on December 17, 2026

CEO pay $885K

04 Nov 2026 Form 4: Abrams Michael S, Chief Financial Officer

Granted 75,000 Restricted Stock Unit

04 Nov 2026 Form 4: Javitt Jonathan C, Director

Granted 150,000 Restricted Stock Unit

02 Nov 2026 8-K: Regulation FD Disclosure

Preservative-Free Ketamine is an American-manufactured presentation of ketamine that contains no benzethonium chloride (BZT), a toxic antimicrobial preservative that is not Generally Recognized as Safe (GRAS) by the FDA. Current law requ...

16 Oct 2026 8-K: Other Events

On October 16, 2026, the board of directors (the “Board”) of NRx Pharmaceuticals, Inc. (the “Company”) established December 17, 2026 as the date of the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) and set October 28, 2...

05 Oct 2026 8-K: Entry into a Material Definitive Agreement

NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression

16 Sep 2026 8-K: Other Events

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine

14 Sep 2026 8-K: Regulation FD Disclosure

On September 8, 2026, representatives of NRx Pharmaceuticals, Inc. (the “Company”) used the investor presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K in connection with presentations and meetings with investors a...

17 Aug 2026 8-K: Results of Operations and Financial Condition

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

14 Aug 2026 FORM 10-Q
07 Aug 2026 8-K: Regulation FD Disclosure

As previously disclosed, NRx Pharmaceuticals Inc. (the “Company”) filed an Abbreviated New Drug Application (“ANDA”) for preservative free ketamine in September 2025. The FDA advised the Company on July 30, 2026 of a final determination ...

22 Jul 2026 8-K: Other Events

In April 2026, NRx Pharmaceuticals, Inc. (the “Company”) announced the incorporation of NRx Defense Systems, Inc. (“NRXD”), a Florida-based research and development subsidiary charged with the development of neuroplastic treatments that ...

04 Jun 2026 8-K: Entry into a Material Definitive Agreement; Other Events

NRx Pharmaceutics, Inc., a Delaware corporation (the “Company”) proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters,” which term shall also include any underwriter substituted as hereinafter prov...

03 Jun 2026 FORM 424B5
02 Jun 2026 8-K: Other Events

WILMINGTON, Del., June 2, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it intends to offer shares of its comm...

02 Jun 2026 FORM 424B5
22 May 2026 25-NSE
15 May 2026 FORM 10-Q

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support